Amgen's biosimilar of AbbVie's Humira enters US market
Sundry Photography/iStock Editorial via Getty Images


Amgen (NASDAQ:AMGN) said Amjevita (adalimumab-atto), a biosimilar to AbbVie's (NYSE:ABBV) blockbuster drug Humira (adalimumab), is now available in the U.S.
Amgen said Amjevita was the first biosimilar to Humira approved by the U.S. Food and Drug Administration (FDA), in 2016.

Amjevita is available at a list price (Wholesale Acquisition Cost) 55% below the current Humira list price. The biosimilar is also available at a list price 5% below the current Humira list price, Amgen noted.
"With today's announcement, AMJEVITA is the first U.S. biosimilar to Humira, a medicine used by more than a million patients living with certain serious inflammatory diseases," said Murdo Gordon, executive vice president of Global Commercial Operations at Amgen.
Humira, which generated $21B in worldwide sales for AbbVie in 2021, became the world's top-selling drug for the tenth consecutive year.
However, Humira dominance will hit a roadblock as copycat versions enter the U.S. market.
AMGN +0.56% to $253 premarket Jan. 31